The stock of NLS Pharmaceutics Ltd (NLSP) has gone up by 15.77% for the week, with a 20.26% rise in the past month and a 82.35% rise in the past quarter. The volatility ratio for the week is 8.74%, and the volatility levels for the past 30 days are 9.23% for NLSP. The simple moving average for the past 20 days is 19.15% for NLSP’s stock, with a 5.01% simple moving average for the past 200 days.
Is It Worth Investing in NLS Pharmaceutics Ltd (NASDAQ: NLSP) Right Now?
NLSP has 36-month beta value of 0.09. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for NLSP is 2.08M, and currently, short sellers hold a 3.48% ratio of that float. The average trading volume of NLSP on June 30, 2025 was 246.63K shares.
NLSP) stock’s latest price update
NLS Pharmaceutics Ltd (NASDAQ: NLSP)’s stock price has soared by 9.84 in relation to previous closing price of 2.54. Nevertheless, the company has seen a gain of 15.77% in its stock price over the last five trading days. prnewswire.com reported 2025-06-16 that ZURICH , June 16, 2025 /PRNewswire/ — NLS Pharmaceutics Ltd. (NASDAQ: NLSP), a Swiss clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system (CNS) disorders, today issued a letter to its shareholders.
NLSP Trading at 43.97% from the 50-Day Moving Average
After a stumble in the market that brought NLSP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -82.56% of loss for the given period.
Stock Fundamentals for NLSP
The total capital return value is set at 0.32.
Based on NLS Pharmaceutics Ltd (NLSP), the company’s capital structure generated -0.23 points at debt to capital in total, while cash flow to debt ratio is standing at -0.89. The debt to equity ratio resting at -0.18. The interest coverage ratio of the stock is -14.19.
Currently, EBITDA for the company is -11.8 million with net debt to EBITDA at -0.18. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.69.
Conclusion
To put it simply, NLS Pharmaceutics Ltd (NLSP) has had a better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
